NovoCure Ltd. (NVCR)
NASDAQ · Healthcare
NovoCure Ltd. EBITDA 2013–2025
NovoCure Ltd. annual/quarterly ebitda history and growth rate from 2013 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- NovoCure Ltd. ebitda for the quarter ending March 31, 2026 was -63.3 M, a 83.25% increase year-over-year.
- NovoCure Ltd. ebitda for the twelve months ending March 31, 2026 was -166.3 M, a 7.62% increase year-over-year.
- NovoCure Ltd. annual ebitda for 2025 was -139.2 M, a 12.63% decrease from 2024.
- NovoCure Ltd. annual ebitda for 2024 was -159.3 M, a 28.23% decrease from 2023.
- NovoCure Ltd. annual ebitda for 2023 was -221.9 M, a 181.25% increase from 2022.
- NovoCure Ltd. annual ebitda for 2022 was -78.9 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
NovoCure Ltd. EBITDA — FAQ
NovoCure Ltd. (NVCR) ebitda over the last 13 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see NVCR's ebitda history?
The chart and table above show NovoCure Ltd.'s ebitda by year and by quarter, including the growth rate.